psalexa
logo

Hepatitis Drugs Market

Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 – Industry Insights by Type (Hepatitis A, Hepatitis B, Hepatitis C, and Others), by Hepatitis B Drugs (Baraclude, Viread, Tyzeka, Hepsera, and Others), and By Hepatitis C Drugs (Sovaldi, OLYSIO, Harvoni, Pegasys, PegIntron, Victrelis, and Others)

Published: December 2015
Report Code: LS10539
Available Format:
Pages: 87

Chapter 1. Research Scope & Methodology

1.1 Market Definition

1.2 Objective

1.3 Market Scope

1.3.1 Market breakdown by segment

1.3.2 Market breakdown by geography

1.4 Research Methodology and Sources    

Chapter 2. Executive Summary   

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Global Trend in Hepatitis Drugs Market

3.2.1 Increasing number of collaborations and partnerships

3.3 Factors Driving the Growth of the Market and its Impact on Market Forecast       

3.3.1 Increasing incidences of hepatitis

3.3.2 Increasing support from government organizations

3.3.3 Growing geriatric population  

3.3.4 Increasing R&D investments in hepatitis research and drug discovery     

3.3.5 Impact analysis of drivers on market forecast

3.4 Factors Hindering the Market and its Impact on Market Forecast     

3.4.1 High capital expenditure

3.4.2 Stringent regulatory requirements    

3.4.3 Impact analysis of restraints on market forecast   

Chapter 4. Global Hepatitis Drugs Market Size and Forecast     (2011 – 2020)

4.1 Global Hepatitis Drugs Market Breakdown by Type

4.2 Global Hepatitis Drugs Market Breakdown by Geography      

Chapter 5. Global Hepatitis Drugs Market Breakdown by Type

5.1 Hepatitis C Drugs Market

5.1.1 Hepatitis C drugs market segmentation by region   

5.1.2 Hepatitis C drugs market segmentation by drugs    

5.2 Hepatitis B Drugs Market

5.2.1 Hepatitis B drugs market segmentation by region   

5.2.2 Hepatitis B drugs market segmentation by drugs    

5.3 Hepatitis A Drugs Market

5.3.1 Hepatitis A drugs market segmentation by region   

Chapter 6. Global Hepatitis Drugs Market Breakdown by     Geography

6.1 North America Hepatitis Drugs Market

6.1.1 North America hepatitis drugs market breakdown by type

6.1.2 North America hepatitis drugs market breakdown by country

6.2 Europe Hepatitis Drugs Market

6.2.1 Europe hepatitis drugs market breakdown by type

6.2.2 Europe hepatitis drugs market breakdown by country

6.3 Asia Hepatitis Drugs Market

6.3.1 Asia hepatitis drugs market breakdown by type

6.3.2 Asia hepatitis drugs market breakdown by country

6.4 Rest of the World Hepatitis Drugs Market

6.4.1 RoW hepatitis drugs market breakdown by type

Chapter 7. Pipeline Drugs for Hepatitis

Chapter 8. Drug Approval Process in the .S. and EU

8.1 Drug approval process in the U.S.

8.2 Drug Approval in the EU

Chapter 9. Competitive Positioning and Market Share Analysis

9.1 Porter's Five Forces of Competitive Position Analysis

9.1.1 Bargaining power of buyers

9.1.2 Bargaining power of suppliers

9.1.3 Threat of new entrants

9.1.4 Intensity of rivalry

9.1.5 Threat of substitutes

9.2 Global Hepatitis Drugs Market Share Analysis

Chapter 10. Company Profiles and Strategic Developments

10.1 Key Company Profiles

10.1.1 Gilead Sciences Inc.

10.1.1.1 Business overview

10.1.1.2 Product and service offerings

10.1.2 F. Hoffmann-La Roche Ltd

10.1.2.1 Business overview

10.1.2.2 Product and service offerings

10.1.3 Johnson & Johnson

10.1.3.1 Business overview

10.1.3.2 Product and services offerings

10.1.4 Merck & Co., Inc.

10.1.4.1 Business overview

10.1.4.2 Product and service offerings

10.1.5 GlaxoSmithKline plc

10.1.5.1 Business overview

10.1.5.2 Product and service offerings

10.1.6 AbbVie Inc.

10.1.6.1 Business overview 

10.1.6.2 Product and service offerings

10.1.7 Novartis AG

10.1.7.1 Business overview

10.1.7.2 Product and service offerings

10.1.8 Bristol-Myers Squibb Company

10.1.8.1 Business overview

10.1.8.2 Product and service offerings

10.1.9 Dynavax Technologies Corporation 

10.1.9.1 Business overview

10.1.9.2 Product and service offerings

10.1.10 Mitsubishi Tanabe Pharma Corporation

10.1.10.1 Business overview

10.1.10.2 Product and service offerings

10.2 Strategic Developments in the Hepatitis Drugs Market

10.2.1 Mergers & acquisitions

10.2.2 Collaborations & partnerships

10.2.3 Marketing authorization

10.2.4 Product launch

10.2.5 Application filling

10.2.6 Pipeline newscast

10.2.7 Others

Chapter 11. Appendix

11.1 List of Abbreviations    

LIST OF TABLES

TABLE 1        SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2        GLOBAL HEPATITIS DRUGS MARKET SNAPSHOT

TABLE 3        MAJOR COLLABORATION AND PARTNERSHIPS IN HEPATITIS DRUGS MARKET (2015)   

TABLE 4        DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5        RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6        GLOBAL HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)

TABLE 7        GLOBAL HEPATITIS DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)

TABLE 8        GLOBAL HEPATITIS C DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)

TABLE 9        GLOBAL HEPATITIS C DRUGS MARKET BREAKDOWN BY DRUGS, $M (2015–2020)

TABLE 10       GLOBAL HEPATITIS B DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)

TABLE 11       GLOBAL HEPATITIS B DRUGS MARKET BREAKDOWN BY DRUGS, $M (2015 – 2020)

TABLE 12       GLOBAL HEPATITIS A DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)

TABLE 13       NORTH AMERICA HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)

TABLE 14       NORTH AMERICA HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 – 2020)

TABLE 15       EUROPE HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)

TABLE 16       EUROPE HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 – 2020)

TABLE 17       ASIA HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)

TABLE 18       ASIA HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 – 2020)

TABLE 19       ROW HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)

TABLE 20       DRUGS UNDER DEVELOPMENT FOR CHRONIC HEPATITIS B, 2015

TABLE 21       CLINICAL TRIAL STAGES OF HEPATITIS C DRUGS, 2015

TABLE 22       GILEAD SCIENCES INC.– KEY FACTS

TABLE 23       F. HOFFMANN-LA ROCHE LTD – KEY FACTS

TABLE 24       JOHNSON & JOHNSON – KEY FACTS

TABLE 25       MERCK & CO., INC. – KEY FACTS

TABLE 26       GLAXOSMITHKLINE PLC – KEY FACTS

TABLE 27       ABBVIE INC. – KEY FACTS

TABLE 28       NOVARTIS AG – KEY FACTS

TABLE 29       BRISTOL-MYERS SQUIBB COMPANY – KEY FACTS

TABLE 30       DYNAVAX TECHNOLOGIES CORPORATION KEY FACTS

TABLE 31       MITSUBISHI TANABE PHARMA CORPORATION - KEY FACTS

 

 LIST OF FIGURES

FIG 1  RESEARCH SCOPE FOR GLOBAL HEPATITIS DRUGS MARKET

FIG 2  RESEARCH METHODOLOGY FOR GLOBAL HEPATITIS DRUGS MARKET

FIG 3  TYPES OF HEPATITIS

FIG 4  MAJOR SYMPTOMS OF HEPATITIS

FIG 5  DIAGNOTSIC PROCEDURES FOR HEPATITIS

FIG 6  KEY DRUGS USED TO TREAT HEPATITIS B AND HEPATITIS C

FIG 7  AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION IN MAJOR COUNTRIES

FIG 8  BASIC DRUG DEVELOPMENT PROCEDURE

FIG 9  GLOBAL HEPATITIS DRUGS MARKET SIZE BY TYPE, $M (2014 – 2020)

FIG 10 GLOBAL HEPATITIS DRUGS MARKET SIZE BY GEOGRAPHY, $M (2014 – 2020)   

FIG 11 GLOBAL HEPATITIS C DRUGS MARKET SIZE, $M (2014 – 2020)  

FIG 12 GLOBAL HEPATITIS C DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 13 GLOBAL HEPATITIS C DRUGS MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 14 GLOBAL HEPATITIS C DRUGS MARKET SIZE BY DRUGS, $M (2014 – 2020)

FIG 15 GLOBAL HEPATITIS B DRUGS MARKET SIZE, $M (2014 – 2020)

FIG 16 GLOBAL HEPATITIS B DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 17 GLOBAL HEPATITIS B DRUGS MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 18 GLOBAL HEPATITIS B DRUGS MARKET SIZE BY DRUGS, $M (2014 – 2020)

FIG 19 GLOBAL HEPATITIS A DRUGS MARKET SIZE, $M (2014 – 2020)

FIG 20 GLOBAL HEPATITIS A DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 21 GLOBAL HEPATITIS A DRUGS MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 22 GLOBAL HEPATITIS DRUGS MARKET SIZE, BY GEOGRAPHY

FIG 23 NORTH AMERICA HEPATITIS DRUGS MARKET SIZE, $M (2014 – 2020)   

FIG 24 NORTH AMERICA HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 25 NORTH AMERICA HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 26 EUROPE HEPATITIS DRUGS MARKET SIZE, $M (2014 – 2020)

FIG 27 EUROPE HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 28 EUROPE HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 29 ASIA HEPATITIS DRUGS MARKET SIZE, $M (2014 – 2020)

FIG 30 ASIA HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 31 ASIA HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 32 ROW HEPATITIS DRUGS MARKET SIZE, $M (2014 – 2020)

FIG 33 ROW HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 34 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 35 MARKET SHARE OF KEY PLAYERS IN THE GLOBAL HEPATITIS DRUGS MARKET (2014)

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7500

Pre-Purchase Enquiry